Skip to main content

Advertisement

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis

  • Nuran Bektas Serce1,
  • Andreas Boesl2,
  • Irina Klaman3,
  • Sonja von Serényi4,
  • Erik Noetzel4,
  • Michael F Press5,
  • Arno Dimmler6,
  • Arndt Hartmann7,
  • Jalid Sehouli8,
  • Ruth Knuechel4,
  • Matthias W Beckmann9,
  • Peter A Fasching9, 10 and
  • Edgar Dahl4Email author
BMC Cancer201212:597

DOI: 10.1186/1471-2407-12-597

Received: 9 September 2012

Accepted: 6 December 2012

Published: 13 December 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
9 Sep 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
15 Sep 2012 Reviewed Reviewer Report - Hiroko Yamashita
28 Sep 2012 Reviewed Reviewer Report - Yiannis Drosos
14 Nov 2012 Author responded Author comments - Nuran Bektas Serce
Resubmission - Version 3
14 Nov 2012 Submitted Manuscript version 3
19 Nov 2012 Reviewed Reviewer Report - Hiroko Yamashita
29 Nov 2012 Reviewed Reviewer Report - Yiannis Drosos
3 Dec 2012 Author responded Author comments - Nuran Bektas Serce
Resubmission - Version 4
3 Dec 2012 Submitted Manuscript version 4
Publishing
6 Dec 2012 Editorially accepted
13 Dec 2012 Article published 10.1186/1471-2407-12-597

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Department of Pathology, University Hospital Bonn
(2)
Department of Pathology, Vorarlberger Krankenhaus-Betriebsgesellschaft m.b.H. Hospital
(3)
Signature Diagnostics AG
(4)
Molecular Oncology Group, Institute of Pathology, University Hospital of the RWTH Aachen
(5)
Department of PathologyKeck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center
(6)
Department of Pathology, St.-Vincentius-Kliniken
(7)
Department of Pathology, University Hospital Erlangen
(8)
Department of Gynaecology, Charité Campus Virchow-Klinikum
(9)
Department of Gynaecology, University Hospital Erlangen
(10)
David Geffen School of Medicine, Division of Hematology and Oncology, University of California at Los Angeles

Advertisement